



November 11, 2021

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Disclosure of the Outcome of the Meeting of the Board of Directors of HealthCare Global Enterprises Limited ("the Company") held on November 11, 2021

Stock Code : BSE – 539787, NSE – HCG

Reference : Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations 2015")

We wish to inform you that the Board of Directors of the Company ("Board"), at their meeting held on this day, November 11, 2021, *inter alia*, has considered and approved the following agenda:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021;
2. Issue and allotment of 72,800 (Seventy-Two Thousand Eight Hundred) equity shares of the Company of INR 10 each, upon exercise of Employee Stock Options in accordance with the Employee Stock Option Scheme 2014.
3. Appointment of Mr. Jeyandran Venugopal (DIN: 07085479) as an Additional Director - Independent Non-Executive Director for a term of 3 years, with effect from November 11, 2021, who shall not be liable to retire by rotation. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations, 2015 in this regard.
4. Investment of up to INR 33 Crore in the equity shares of Suchirayu Health Care Solutions Limited ("Suchirayu") through preferential issuance, for acquiring a shareholding of up to 80% in Suchirayu; and further purchase of equity shares from other shareholders of Suchirayu, for a consideration not exceeding INR 5 Crore. Detailed intimation in this regard in terms of Regulation 30 of SEBI LODR Regulations, 2015 will be submitted to the Stock Exchanges, upon the Company consummating the investment/acquisition of shares in Suchirayu. The Company presently holds 17.7% of the equity shares of Suchirayu.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:


1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2021;
2. Limited Review Report of the Statutory Auditors on the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021.

The Meeting of the Board of Directors commenced at 10.30 a.m. and concluded at 4.45 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**



Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,
Pebble Beach, B Block, 3rd Floor,
Off Intermediate Ring Road,
Bengaluru-560 071 India

Telephone: + 91 80 4682 3000
Fax: + 91 80 4682 3999

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited ("the Company") for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 2 in the unaudited standalone financial results, which describes the economic and social consequences the Company is facing as a result of COVID-19 which is impacting supply chains/demand/personnel available for work and/or being able to access offices/hospitals.
Our conclusion is not modified in respect of this matter

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No. 101248W/W-100022



Amit Somani
Partner

Place: Bengaluru
Date: 11 November 2021

Membership No.060154
UDIN: 21060154AAAACV4154

Registered Office:

HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P. Kalanga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

(Rs. in Lakhs except share data)						
Sl. No.	Particulars	Quarter ended 30 September 2021	Preceding quarter ended 30 June 2021	Corresponding quarter ended 30 September 2020	Six months ended 30 September 2021	Previous year ended 31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	(a) Revenue from operations	21,517	20,010	14,506	41,527	60,886
	(b) Income from government grant	49	50	50	99	217
	(c) Other income	154	453	556	607	2,185
	Total Income	21,720	20,513	15,112	42,233	63,288
2	Expenses					
	(a) Purchases of medical and non-medical items	5,379	5,862	3,285	11,241	13,799
	(b) Changes in inventories	306	(711)	(30)	(405)	56
	(c) Employee benefits expense	3,845	3,882	3,413	7,727	13,672
	(d) Finance costs	1,035	1,250	1,309	2,285	6,286
	(e) Depreciation and amortisation expense	2,130	2,097	2,185	4,227	8,658
	(f) Medical consultancy charges	3,830	3,700	2,828	7,530	11,629
	(g) Other expenses	4,467	4,240	3,345	8,707	14,392
	Total expenses	20,992	20,320	16,335	41,312	68,483
3	Profit / (loss) before exceptional items and tax (1-2)	728	193	(1,223)	921	(5,195)
4	Exceptional items net gain / (loss) (refer note 4)	12,542	-	-	12,542	(15,310)
5	Profit / (loss) before tax (3-4)	13,270	193	(1,223)	13,463	(20,505)
6	Tax expense					
	- Current tax	1,179	43	-	1,222	-
	- Deferred tax	2,701	10	(565)	2,711	(1,351)
	Total tax expense / (credit)	3,880	53	(565)	3,933	(1,351)
7	Profit / (loss) for the period / year (5-6)	9,390	140	(658)	9,530	(19,154)
8	Other comprehensive Income / (loss)					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	-	-	-	-	(21)
	- Income tax effect on (i) above	-	-	-	-	7
	(ii) Items that will be reclassified to profit or loss					
	- Effective portion of gain on hedging instruments in a cash flow hedge	-	118	158	118	447
	- Income tax effect on (ii) above	-	(41)	(55)	(41)	(156)
	Other comprehensive Income / (loss) for the period / year, net of tax	-	77	103	77	277
9	Total comprehensive Income / (loss) for the period / year (7+8)	9,390	217	(555)	9,607	(18,877)
10	Paid-up equity share capital (Face value of Rs. 10 each)	12,542	12,539	12,526	12,542	12,526
11	Reserves, i.e. 'Other equity'					79,842
12	Earnings / (Loss) per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	7.49	0.11	(0.57)	7.60	(16.85)
	(b) Diluted *	7.00	0.11	(0.57)*	7.15	(16.85)*
	* Since there is a loss during previous year / period, potential equity shares are not considered as dilutive and accordingly diluted loss per share is same as basic loss per share					
	See accompanying notes to the Standalone Financial Results					



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalanga Rao Road, Sampangi Ramu Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

STANDALONE BALANCE SHEET		(Rs in Lakhs)	
Particulars	As at 30 September 2021	As at 31 March 2021	
	Unaudited	Audited	
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment	49,141	49,741	
(b) Capital work in progress	3,651	2,761	
(c) Right-of-use assets	16,995	18,042	
(d) Goodwill	11,068	4,845	
(e) Other intangible assets	1,395	1,889	
(f) Financial assets			
(i) Investments	39,959	36,566	
(ii) Loans receivable	1,275	1,320	
(iii) Other financial assets	2,720	2,622	
(g) Deferred tax assets (net)	-	2,733	
(h) Income tax assets (net)	2,704	3,075	
(i) Other non-current assets	1,187	1,059	
Total non-current assets	130,095	124,653	
II Current assets			
(a) Inventories	1,841	1,195	
(b) Financial assets			
(i) Trade receivables	17,085	14,748	
(ii) Cash and cash equivalents	1,375	1,446	
(iii) Loans receivable	285	351	
(iv) Other financial assets	11,985	13,488	
(c) Other current assets	1,657	1,571	
Total current assets	34,228	32,799	
Total assets	164,323	157,452	
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	12,542	12,536	
(b) Other equity	89,414	79,842	
Total equity	101,956	92,378	
II Liabilities			
1 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	10,790	14,713	
(ii) Lease liability	21,570	22,195	
(iii) Other financial liabilities	609	624	
(b) Provisions	683	629	
(c) Deferred tax liabilities (net)	19	-	
(d) Other non-current liabilities	1,842	1,921	
Total non-current liabilities	35,513	40,082	
2 Current liabilities			
(a) Financial liabilities			
(i) Borrowings	9,496	9,239	
(ii) Lease liability	1,663	1,993	
(iii) Trade payables			
Total outstanding dues of micro enterprises and small enterprises	-	27	
Total outstanding dues of creditors other than micro enterprises and small enterprises	9,419	8,102	
(iv) Other financial liabilities	2,290	2,634	
(b) Other current liabilities	2,533	2,131	
(c) Provisions	1,453	866	
Total current liabilities	26,854	24,992	
Total equity and liabilities	164,323	157,452	

See accompanying notes to the Standalone Financial Results



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P. Kalanga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

Standalone Cash Flow Statement		
Particulars	(Rs in Lakhs)	
	For the six months ended 30 September 2021	For the six months ended 30 September 2020
	Unaudited	Unaudited
Cash flows from operating activities		
Profit / (loss) before tax	13,463	(4,050)
Adjustments for:		
Finance costs	2,285	3,608
Gain on investment revalued at FVTPL	(10)	-
Guarantee commission income	(90)	(135)
Loss / (gain) on disposal of property, plant and equipment	1	-
Provision for bad and doubtful receivables and expenses on employee stock option scheme	285	255
Interest income	(457)	(745)
Income from government grant	(99)	(101)
Depreciation and amortisation expense	4,227	4,370
Net foreign exchange loss/(gain)	(9)	15
Exceptional items (refer note 4)	(12,542)	-
Movements in working capital:		
Changes in trade receivables	(2,699)	143
Changes in inventories	(405)	22
Changes in loans, financial assets and other assets	(508)	723
Changes in trade payables, financial liabilities and other liabilities	647	(5,612)
Changes in provisions	56	141
Cash generated from operations	4,145	628
Income taxes paid (net of refunds)	(850)	1,276
Net cash generated from operating activities (A)	3,295	1,904
Cash flows from investing activities		
Fixed deposits, earmarked against credit facility	(8,216)	(13,050)
Proceeds from maturity of margin money deposits	10,936	557
Acquisition of property, plant and equipment	(1,667)	(457)
Payment towards contingent consideration	-	(640)
Interest received	322	146
Investment in subsidiaries	(5,491)	(2,379)
Payment for acquisition of business, including acquisition expenses [Refer note 7]	(7,430)	-
Proceeds from sale of investment in joint venture (net of expenses incurred towards sale of investment) [Refer note 4(v)(a)]	15,770	-
Proceeds from repayment of Inter-corporate deposits	45	25
Payment of share application money	-	(25)
Proceeds from repayments of related party loans	-	190
Net cash generated / (used) in investing activities (B)	4,270	(15,633)
Cash flows from financing activities		
Proceeds from issue of equity shares and warrants	35	51,934
Share issue expenses	-	(2,321)
Repayment of loan from related parties	-	(1,499)
Proceeds from bills discounting	2,528	-
Bills discounted settled	(6,316)	-
Proceeds from long-term borrowings	8,558	1,235
Repayment of long-term borrowings	(12,139)	(22,728)
Loan foreclosure and refinancing expenses [Refer note 4(i)(b)]	(503)	-
Repayment of principal portion of lease liability	(1,034)	(692)
Interest paid on lease liability	(1,295)	-
Interest and other borrowing cost paid	(1,082)	(3,423)
Net cash generated from / (used in) financing activities (C)	(11,448)	22,506
Net Increase/ (decrease) in cash and cash equivalents (A+B+C)	(3,883)	8,777
Cash and cash equivalents at the beginning of the period	(1,267)	(7,386)
Cash and cash equivalents at the end of the period	(5,150)	1,391

Break up of cash and cash equivalents at the end of the period	As at 30 September 2021	As at 30 September 2020
Cash and cash equivalents at the end of the period	1,375	1,780
Deposits with a original maturity less than 3 months	-	8,196
Less: Bank overdrafts repayable on demand (including accrued interest of Rs Nil ; 30 Sep 2020: Rs 15 lakhs)	(6,525)	(8,585)
Cash and cash equivalents at the end of the period	(5,150)	1,391



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P. Kalunga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

Notes:

- 1 The statement of unaudited standalone financial results (the Statement) of HealthCare Global Enterprises Limited (the Company) for the quarter and six months ended 30 September 2021 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 November 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.

- 2 **Impact of COVID-19 pandemic:**

The measures put in place to control the spread of virus, including the travel restrictions adversely impacted the patients' footfall and the healthcare workers during the early part of the previous year. Following the easing of lockdown restrictions and pursuant to various measures taken by the management to adapt to the changing circumstances, the Company was able to gradually recover. While there has been resurgence of Covid infections from March 2021 and different forms of restrictions were imposed by various state governments and local bodies to control of the pandemic, impact on the Company's operations is not as severe as the lockdown during first wave. The management will continue to monitor changes to the future economic conditions for any material impact, including on its new projects, as the situation evolves.

Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of the Company's liquidity position and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.

- 3 a) During the previous year ended 31 March 2021, the Company made preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,569,663 Warrants with a right to apply for and be allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) to Access Company (Pte. Ltd., Singapore ("Investor") on 28 July 2020. As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations"), Investor remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) that was converted into equity and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.

b) During the previous year, on 28 July 2020, the Company also made preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant) to Promoter Shareholder. As required under the provisions of the ICDR Regulations, an amount equivalent to 25% of the consideration i.e., Rs. 650 lakhs was received on issue of series B Warrants and the remaining 75% of the consideration i.e., 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.

- 4 **Exceptional Items:**

- (i) **For quarter and six months ended 30 September 2021:**

- a) During the quarter, the Company sold its investment in Strand Life Sciences Private Limited ("Strand") for a total consideration of Rs. 15,778 lakhs, resulting in a gain of Rs. 12,769 lakhs (net of expenses / other provisions).

- b) The Company has refinanced its certain borrowings from banks and financial institutions. On account of this, the Company has incurred one time expenses of Rs. 172 lakhs, net, towards foreclosure charges and accelerated amortization of loan processing fees related to earlier borrowings, which has been disclosed under Exceptional Items.

- (ii) **For the year ended 31 March 2021:**

- a) During the previous year ended 31 March 2021, the Company performed impairment assessment for all its investments in the subsidiaries, joint ventures and other parties. Given the continued losses incurred and weaker forecasts primarily due to COVID-19, the recoverable amount of investments (considering the future cash flows) was estimated to be lower than their carrying value, resulting into an impairment charge with respect to HCGC HealthCare Private Limited amounting to Rs. 5,884 lakhs, Apex HCG Oncology Hospitals LLP amounting to Rs. 1,600 lakhs, HCG EKO Oncology LLP amounting to Rs. 120 lakhs and other parties amounting to Rs. 176 lakhs respectively.

- b) During the previous year ended 31 March 2021, the Company assessed the recoverable value of its investment made in the upcoming greenfield project in Gujarat. The assessment was made considering significant change in scope, delays in project due to changes in management plan, market conditions including the outbreak of COVID-19 pandemic. The recoverable amount of this project (considering the future cash flows) was estimated to be lower than carrying value, resulting into an impairment charge of Rs. 3,630 lakhs during the year ended 31 March 2021.

- c) During the previous year ended 31 March 2021, due to changes in business environment and weaker project viability due to COVID-19, the Cochun project was abandoned. Hence an amount of Rs. 875 lakhs was "written off".

- d) During the previous year ended 31 March 2021, due to COVID-19, the Company assessed the recoverable amount of certain class of assets and estimated that those class of assets may not be recoverable, resulting into an impairment charge amounting to Rs. 805 lakhs.

- e) The Company has invested in Healthcare Global (Africa) Pvt. Ltd. ("HCG Africa") through its wholly owned subsidiaries. During the previous year, CDC Group PLC, ("CDC") (other investor in HCG Africa) exercised the put option in accordance with the agreement to exit HCG Africa. The Company performed impairment assessment basis which the recoverable amount of investment/delisted loans was estimated to be lower than carrying value. Accordingly, loan along with interest accrued of Rs. 2,797 lakhs was impaired during the previous year ended 31 March 2021.

- f) During the previous year ended 31 March 2021 for one lease arrangement, the Company negotiated lower lease rent for reduced space and the resulting gain on modification of Rs. 577 lakhs was recognised.

- 5 The Code on Social Security 2020 ("Code"), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Code will have an impact on the contributions towards gratuity and provident fund made by the Company. The Ministry of Labour and Employment ("Ministry") has released draft rules for the Code on 13 November 2020. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. The Company will assess the impact once the subject rules are notified and will give appropriate impact in its financial results in the period in which, the Code becomes effective.

- 6 Pursuant to the amendment to Schedule III of the Companies Act, 2013, effective from 1 April 2021, non-current security deposits of Rs. 1,959 Lakhs and current security deposits of Rs. 207 Lakhs as at 31 March 2021 have been reclassified from 'Loans receivable' to 'Other financial assets' and current maturities of long-term borrowings amounting Rs. 2,537 Lakhs as at 31 March 2021 have been reclassified from 'Other financial liabilities' to 'short-term borrowings'.

- 7 During the quarter, the Company entered into Business Transfer Agreement (BTA) with Strand for acquisition of the diagnostic business and the division providing clinical research site management services for a total consideration of Rs. 8,080 Lakhs. Of the total consideration, Rs. 7,400 has been paid and the balance amount is payable as per the timeline specified in the BTA. With the acquisition of these businesses, the earlier outsourced Hospital Lab Management services has been cancelled. Further, a preliminary purchase price allocation of the total consideration has been done at the acquisition date and has been incorporated in the Statement.

- 8 The Company has a single operating segment of "setting up and managing hospitals and medical diagnostic services".

Bengaluru, 11 November 2021


Dr. B. S. Ajith Kumar
Executive Chairman



B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,
Pebble Beach, B Block, 3rd Floor,
Off Intermediate Ring Road,
Bengaluru-560 071 India

Telephone: + 91 80 4682 3000
Fax: + 91 80 4682 3999

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

To

Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its associate and a joint venture for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (continued)

4. The Statement includes the results of the following entities:

Sl. No.	Name of the Entity	Subsidiary/ Associate/ Joint Venture	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group	Step-down subsidiary (w.e.f. 30 September 2021) Associate (upto 29 September 2021)	Mauritius
15	Healthcare Global (Uganda) Private Limited	Step-down subsidiary (w.e.f. 30 September 2021)	Uganda
16	Healthcare Global (Tanzania) Private Limited	Step-down subsidiary (w.e.f. 30 September 2021)	Tanzania
17	Healthcare Global (Kenya) Private Limited	Step-down subsidiary (w.e.f. 30 September 2021)	Kenya
18	Cancer Care Kenya Limited	Step-down subsidiary (w.e.f. 30 September 2021)	Kenya
19	Advanced Molecular Imaging Limited	Joint Venture (w.e.f. 30 September 2021)	Kenya
20	Strand Life Sciences Private Limited	Joint Venture (upto 2 September 2021)	India

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note 2 in the unaudited consolidated financial results, which describes the economic and social consequences the Group is facing as a result of COVID-19 which is impacting supply chains/demand/personnel available for work and/or being able to access offices/hospitals. Our conclusion is not modified in respect of this matter.
7. We did not review the financial information / financial results of six (6) subsidiaries and six (6) step down subsidiaries included in the Statement, whose financial information / financial results reflect total assets of Rs 22,677 lakhs as at 30 September 2021 and total revenues of Rs 2,563 lakhs and Rs. 5,191 lakhs, total net loss after tax of Rs 266 lakhs and Rs 1,069 lakhs and total comprehensive loss of Rs 230 lakhs and Rs 1,027 lakhs, for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021, respectively, and cash inflows (net) of Rs 167 lakhs for the period from 1 April 2021 to 30 September 2021, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group's share of net loss of Rs. 200 lakhs and Rs. 143 lakhs and total comprehensive loss of Rs. 452 lakhs and Rs. 240 lakhs for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021, respectively, as considered in the Statement, in respect of an associate and two (2) joint ventures, whose financial information/ financial results have not been reviewed by us. These financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No. 101248W/W-100022



Amit Somani
Partner

Place: Bengaluru
Date: 11 November 2021

Membership No.060154
UDIN: 21060154AAAACW6091

HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P. Kalianga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 September 2021	Preceding quarter ended 30 June 2021	Corresponding quarter ended 30 September 2020	Six months ended 30 September 2021	Six months ended 30 September 2020	Previous year ended 31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	35,125	32,242	24,686	67,367	43,921	100,919
	(b) Income from government grant	71	72	106	143	217	425
	(c) Other income	330	344	401	674	673	1,695
	Total income	35,526	32,658	25,193	68,184	44,811	103,039
2	Expenses						
	(a) Purchases of medical and non-medical items	8,820	9,330	5,950	18,150	10,165	23,816
	(b) Changes in inventories	301	(1,016)	(137)	(715)	118	215
	(c) Employee benefits expense	5,612	5,580	4,908	11,192	9,096	19,694
	(d) Finance costs	2,323	2,638	2,716	4,961	6,455	11,917
	(e) Depreciation and amortisation expense	3,802	3,778	3,960	7,580	7,901	15,922
	(f) Medical consultancy charges	6,990	6,709	5,558	13,699	9,613	22,175
	(g) Other expenses	7,299	6,588	5,511	13,887	10,207	22,885
	Total expenses	35,147	33,607	28,466	68,754	53,555	116,524
3	Profit / (loss) before share of profit/(loss) of an associate / joint venture, exceptional items and tax (1-2)	479	(949)	(3,273)	(570)	(8,744)	(13,485)
4	Share of profit/(loss) of an associate / joint venture	(200)	57	44	(143)	(148)	(36)
5	Profit / (loss) before exceptional items and tax (3+4)	179	(892)	(3,229)	(713)	(8,892)	(13,521)
6	Exceptional items, net gain / (loss) (refer note 4)	14,012	-	-	14,012	-	(9,345)
7	Profit / (loss) before tax (5-6)	14,191	(892)	(3,229)	13,299	(8,892)	(22,866)
8	Tax expense						
	- Current tax	1,350	144	53	1,494	63	471
	- Deferred tax	2,942	216	(582)	3,158	(1,694)	(1,227)
	Total tax expense/ (credit)	4,292	360	(529)	4,652	(1,631)	(756)
9	Profit / (loss) for the period / year (7-8)	9,899	(1,252)	(2,700)	8,647	(7,261)	(22,110)
10	Other comprehensive income / (loss)						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	-	-	-	-	-	(47)
	- Income tax effect on (i) above	-	-	-	-	-	17
	(ii) Items that will be reclassified to profit or loss						
	- Exchange differences on translation of financial statements of foreign operations	(217)	162	(84)	(55)	(167)	(202)
	- Effective portion of gain on hedging instruments in a cash flow hedge	-	116	158	116	230	447
	- Income tax effect on (ii) above	-	(41)	(55)	(41)	(80)	(156)
	Other comprehensive income / (loss) for the period / year, net of taxes	(217)	237	19	20	(17)	59
11	Total comprehensive profit / (loss) for the period / year (9+10)	9,682	(1,015)	(2,681)	8,667	(7,278)	(22,051)
	Profit / (loss) for the period / year attributable to:						
	Owners of the Company	10,309	(957)	(2,229)	9,352	(6,204)	(19,346)
	Non-controlling interests	(410)	(295)	(471)	(705)	(1,057)	(2,764)
	Other comprehensive income / (loss) for the period / year attributable to:						
	Owners of the Company	(217)	237	19	20	(17)	69
	Non-controlling interests	-	-	-	-	-	(10)
	Total comprehensive income / (loss) for the period / year attributable to:						
	Owners of the Company	10,092	(720)	(2,210)	9,372	(6,221)	(19,277)
	Non-controlling interests	(410)	(295)	(471)	(705)	(1,057)	(2,774)
12	Paid-up equity share capital (Face value of Rs. 10 each)	12,542	12,539	12,526	12,542	12,526	12,536
13	Reserves, i.e., 'Other equity'						57,182
14	Earnings / (Loss) per share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	8.22	(0.76)	(1.94)	7.46	(6.09)	(17.02)
	(b) Diluted *	7.69	(0.76)	(1.94)	7.02	(6.09)	(17.02)
	* Since there is a loss during previous period / year, potential equity shares are not considered as dilutive and hence Diluted loss per share is same as Basic loss per share See accompanying notes to the Consolidated Financial Results						



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

CONSOLIDATED BALANCE SHEET		(Rs. In Lakhs)	
Particulars		As at 30 September 2021	As at 31 March 2021
		Unaudited	Audited
A	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	84,585	85,312
	(b) Capital work in progress	3,910	3,001
	(c) Right-of-use assets	39,532	41,143
	(d) Goodwill	15,857	9,634
	(e) Other intangible assets	2,365	2,149
	(f) Investment in equity accounted investee	308	2,055
	(g) Financial assets		
	(i) Investments	583	573
	(ii) Loans receivable	885	930
	(iii) Other financial assets	5,911	5,256
	(h) Deferred tax assets (net)	173	3,431
	(i) Income tax assets (net)	3,682	4,264
	(j) Other non-current assets	2,550	2,317
	Total non-current assets	160,341	160,065
II	Current assets		
	(a) Inventories	3,072	2,111
	(b) Financial assets		
	(i) Trade receivables	21,457	18,661
	(ii) Cash and cash equivalents	3,845	3,000
	(iii) Bank balance other than cash and cash equivalents above	122	1,085
	(iv) Loans receivable	319	394
	(v) Other financial assets	14,411	15,999
	(c) Other current assets	2,838	2,247
	Total current assets	46,054	43,497
	Total assets	206,395	203,562
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	12,542	12,536
	(b) Other equity	66,586	57,182
	Equity attributable to equity holders of the Company	79,128	69,718
	Non-controlling interests	1,562	1,682
	Total equity	80,690	71,400
II	Liabilities		
1	Non-current liabilities		
	(a) Financials Liabilities		
	(i) Borrowings	28,640	34,617
	(ii) Lease liabilities	45,829	46,931
	(b) Provisions	946	862
	(c) Deferred tax liabilities (net)	369	428
	(d) Other non-current liabilities	2,652	2,798
	Total non-current liabilities	78,436	85,636
2	Current liabilities		
	(a) Financials liabilities		
	(i) Borrowings	10,918	12,546
	(ii) Lease liabilities	3,086	3,650
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	-	31
	Total outstanding dues of creditors other than micro enterprises and small enterprises	16,857	14,520
	(iv) Other financial liabilities	7,747	8,440
	(b) Other current liabilities	7,000	6,262
	(c) Provisions	1,641	1,042
	(d) Income tax liabilities (net)	20	35
	Total current liabilities	47,269	46,526
	Total equity and liabilities	206,395	203,562
See accompanying notes to the Consolidated Financial Results			



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P. Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

Consolidated Cash Flow Statement		(Rs In Lakhs)	
Particulars	For the six months ended 30 September 2021	For the six months ended 30 September 2020	
	Unaudited	Unaudited	
Cash flows from operating activities			
Profit / (loss) before tax	13,299	(8,892)	
Adjustments for:			
Finance costs	4,961	6,455	
Gain on investment revalued at FVTPL	(10)	-	
Loss on disposal of property, plant and equipment	1	-	
Provision for bad and doubtful receivables and expenses on employee stock option scheme	475	299	
Interest income	(611)	(616)	
Depreciation and amortisation expense	7,580	7,901	
Income from government grant	(143)	(217)	
Net foreign exchange loss/(gain)	(9)	15	
Share of loss of equity accounted investees	142	148	
Exceptional items (refer note 4)	(14,012)	-	
Movements in working capital:			
Changes in trade receivables	(3,248)	138	
Changes in inventories	(715)	118	
Changes in loans, financial assets and other assets	(1,087)	320	
Changes in trade payables, financial liabilities and other liabilities	2,071	(2,586)	
Changes in provisions	97	171	
Cash generated from operations	8,791	3,254	
Income taxes paid (net of refunds)	(863)	1,625	
Net cash generated from operating activities (A)	7,928	4,879	
Cash flows from investing activities			
Margin money deposits, net	(1,226)	(2,401)	
Fixed deposits, earmarked against credit facility	(8,215)	(13,050)	
Proceeds from maturity of margin money deposits	11,623	557	
Acquisition of property, plant and equipment	(1,985)	(1,320)	
Payment towards contingent consideration	-	(640)	
Interest received	509	167	
Proceeds from repayment of inter-corporate deposits	45	25	
Investment in associate	(137)	-	
Payment of share application money	(25)	(25)	
Acquisition of business, including acquisition expenses (net of cash and cash equivalents) [Refer notes 4(i)(c) and 7]	(8,271)	-	
Proceeds from sale of investment in joint venture (net of expenses incurred towards sale of investment) [Refer note 4(i)(a)]	15,769	-	
Net cash generated / (used) in investing activities (B)	8,087	(16,687)	
Cash flows from financing activities			
Proceeds from issue of equity shares and warrants	35	51,934	
Share issue expenses	-	(2,321)	
Amount received from minority stakeholder in the subsidiaries	-	98	
Repayment of loan from related parties	-	(309)	
Proceeds from bills discounting	2,528	-	
Bills discounted settled	(6,516)	-	
Proceeds from long-term borrowings	15,784	1,240	
Repayment of long-term borrowings	(23,885)	(23,210)	
Loan foreclosure and refinancing expenses	(856)	-	
Repayment of principle portion of lease liability	(1,749)	(1,131)	
Interest paid on lease liability	(2,679)	-	
Interest and other borrowing cost paid	(2,138)	(5,961)	
Net cash generated from/ (used) in financing activities (C)	(19,476)	20,340	
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(3,461)	8,532	
Cash and cash equivalents at the beginning of the period	286	(5,879)	
Cash and cash equivalents at the end of the period	(3,175)	2,653	

Break up of cash and cash equivalents at the end of the period	As at 30 September 2021	As at 30 September 2020
Cash and cash equivalents at the end of the period	3,845	3,065
Deposits with a original maturity less than 3 months	-	8,196
Less: Bank overdrafts repayable on demand (including accrued interest of Rs. Nil : 30 Sep 2020; Rs. 89 lakhs)	(7,020)	(8,608)
Cash and cash equivalents at the end of the period	(3,175)	2,653



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2021

Notes:

- 1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter and six months ended 30 September 2021 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 November 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

'The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.
- 2 **Impact of COVID 19 pandemic:**
The measures put in place to control the spread of virus, including the travel restrictions adversely impacted the patients' footfall and the healthcare workers during the early part of the previous year. Following the easing of lockdown restrictions and pursuant to various measures taken by the management to adapt to the changing circumstances, the Group was able to gradually recover. While there has been resurgence of Covid infections from March 2021 and different forms of restrictions were imposed by various state governments and local bodies to control this second wave of the pandemic, impact on the Group's operations is not as severe as the lockdown during first wave. The management will continue to monitor changes to the future economic conditions for any material impact, including on its new projects, as the situation evolves.

As at the balance sheet date, the Group's current liabilities exceed its current assets. Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of the Group's liquidity position and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.
- 3 a) During the previous year ended 31 March 2021, the Company made preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,560,663 Warrants, with a right to apply for and be allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) to Access Company Pte. Ltd., Singapore ('Investor') on 28 July 2020. As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (the 'ICDR Regulations'), Investor remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) that was converted into equity and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.

b) During the previous year, on 28 July 2020, the Company also made preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant), to Promoter Shareholder. As required under the provisions of the ICDR Regulations, an amount equivalent to 25% of the consideration i.e. Rs. 650 lakhs was received on issue of series B Warrants and the remaining 75% of the consideration i.e. Rs. 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.
- 4 **Exceptional items:**
(i) For quarter and six months ended 30 September 2021:
a) During the quarter, the Company sold its investment in Strand Life Sciences Private Limited ('Strand') for a total consideration of Rs. 15,778 lakhs, resulting in a gain of Rs. 14,194 lakhs (net of expenses / other provisions).

b) The Group has refinanced its certain borrowings from banks and financial institutions. On account of this, the Group has incurred one time expenses of Rs. 750 lakhs, towards foreclosure charges and accelerated amortization of loan processing fees related to earlier borrowings, which has been disclosed under Exceptional Items.

c) As on 30 September 2021, the Group paid CDC Group PLC (CDC) Rs. 411 lakhs towards its put option exercise (refer note 4(ii)(c) below). On account of this settlement, Healthcare Global (Africa) Pvt Ltd (HCG Africa) became 100% subsidiary of the Group with effect from 30 September 2021. The Group remeasured its previously held equity interest in HCG Africa at its fair valuation on acquisition of the additional stake and recognized the resultant gain of Rs. 623 lakhs as an exceptional item in accordance with the applicable Indian Accounting Standard. Further, a preliminary purchase price allocation of the total consideration has been done at the acquisition date and has been incorporated in the Statement.

(ii) For the year ended 31 March 2021:
a) During the previous year ended 31 March 2021, the Group assessed the recoverable value of its investment made in the upcoming greenfield project in Gurgaon. The assessment was made considering significant change in scope, delays in project due to changes in management plan, market conditions including the outbreak of COVID-19 pandemic. The recoverable amount of this project (considering the future cash flows) was estimated to be lower than carrying value, resulting into an impairment charge of Rs. 3,630 lakhs during the year ended 31 March 2021.

b) During the previous year ended 31 March 2021, the Group carried out annual impairment assessment with respect to one of its cash generating unit i.e. BACC Healthcare Private Limited (hereinafter referred to as 'the CGU'). Considering the losses incurred and more importantly the relatively weaker forecasts due to COVID-19, the Company recorded an impairment loss on goodwill amounting to Rs. 1,300 lakhs.

c) During the previous year ended 31 March 2021, due to changes in business environment and weaker project viability due to COVID-19, the Cochín project was abandoned. Hence an amount of Rs. 875 lakhs was 'written off'.

d) During the previous year ended 31 March 2021, due to COVID-19, the Group assessed the recoverable amount of certain class of assets / investments in other parties and estimated that those class of assets/investments in other parties may not be recoverable, resulting into an impairment charge amounting to Rs. 981 lakhs.

e) During the previous year, CDC Group PLC, (CDC), the other investor in Healthcare Global (Africa) Pvt Ltd (HCG Africa), exercised put option to sell its shares in accordance with the terms of Shareholders Agreement. As at 31 March 2021, pending valuation by an independent valuer to ascertain the fair value of such put option shares, the Group assessed the value of put option by using its best estimate and recognised liability of Rs. 380 lakhs. The Group also performed impairment assessment, basis which the recoverable amount of investment was estimated to be lower than carrying value. Accordingly, impairment charge of Rs. 995 lakhs on its investment in Healthcare Global (Africa) Pvt Ltd was recognised during the quarter and year ended 31 March 2021.

f) During the previous year ended 31 March 2021 for one lease arrangement, the Group negotiated lower lease rent for reduced space and the resulting gain on modification of Rs. 577 lakhs was recognised.

g) During the previous year ended 31 March 2021, for certain subsidiaries, the Group de-recognised the deferred government grant amounting to Rs. 1,130 lakhs and also made an additional provision towards estimated duties and taxes (EPGC Licenses) amounting to Rs. 2,141 lakhs.
- 5 The Code on Social Security 2020 ('Code'), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Code will have an impact on the contributions towards gratuity and provident fund made by the Group. The Ministry of Labour and Employment ('Ministry') has released draft rules for the Code on 13 November 2020. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. The Group will assess the impact once the subject rules are notified and will give appropriate impact in its financial results in the period in which, the Code becomes effective.
- 6 Pursuant to the amendment to Schedule III of the Companies Act, 2013, effective from 1 April 2021, non-current security deposits of Rs. 3,579 Lakhs and current security deposits of Rs. 537 Lakhs as at 31 March 2021 have been reclassified from 'Loans receivable' to 'Other financial assets' and current maturities of long-term borrowings amounting Rs. 5,844 Lakhs as at 31 March 2021 have been reclassified from 'other financial liabilities' to 'short-term borrowings'.
- 7 During the quarter, the Company entered into Business Transfer Agreement (BTA) with Strand for acquisition of the diagnostic business and the division providing clinical research site management services for a total consideration of Rs. 8,080 Lakhs. Of the total consideration Rs. 7,400 has been paid and the balance amount is payable as per the timeliness specified in the BTA. With the acquisition of these businesses, the earlier outsourced Hospital Lab Management services has been cancelled. Further, a preliminary purchase price allocation of the total consideration has been done at the acquisition date and has been incorporated in the Statement.
- 8 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors

Dr. H.S. Ananthanarayanan
Executive Chairman

Bengaluru, 11 November 2021

